Home
Home

hepatitis B

FDA asks for more safety data on Dynavax's hepatitis B vaccine

FDA asks for more safety data on Dynavax's hepatitis B vaccine
Reuters

Dynavax: The Path Forward

Dynavax: The Path Forward
Seeking Alpha

Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection

Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection
TheStreet.com

Dynavax slides as FDA rejects adult hep B vaccine

Dynavax slides as FDA rejects adult hep B vaccine
Reuters

Gilead Settles Teva HIV Drug Patent Suit to Avoid Trial

Gilead Settles Teva HIV Drug Patent Suit to Avoid Trial
Bloomberg

U.S. court invalidates patent on Bristol hepatitis B drug

U.S. court invalidates patent on Bristol hepatitis B drug
Reuters

William Blair Analysts Are Gaining Comfort Ahead Of Dynavax's Heplisav PDUFA

William Blair Analysts Are Gaining Comfort Ahead Of Dynavax's Heplisav PDUFA
Seeking Alpha

Dynavax's Heplisav: Vaccinated Against Failure?

Dynavax's Heplisav: Vaccinated Against Failure?
Seeking Alpha

Dynavax Shares Pummelled After FDA Panel

Dynavax Shares Pummelled After FDA Panel
Motley Fool

85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior Analyst

85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior Analyst
Seeking Alpha